CA2622911C - Methods for reducing cd36 expression - Google Patents

Methods for reducing cd36 expression Download PDF

Info

Publication number
CA2622911C
CA2622911C CA2622911A CA2622911A CA2622911C CA 2622911 C CA2622911 C CA 2622911C CA 2622911 A CA2622911 A CA 2622911A CA 2622911 A CA2622911 A CA 2622911A CA 2622911 C CA2622911 C CA 2622911C
Authority
CA
Canada
Prior art keywords
arg
lys
phe
dmt
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2622911A
Other languages
English (en)
French (fr)
Other versions
CA2622911A1 (en
Inventor
Hazel Szeto
Shaoyi Liu
Sunghee Cho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2947343A priority Critical patent/CA2947343C/en
Priority to CA2947341A priority patent/CA2947341C/en
Priority to CA2947340A priority patent/CA2947340C/en
Priority to CA2947333A priority patent/CA2947333A1/en
Priority to CA2947328A priority patent/CA2947328C/en
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Priority to CA2947335A priority patent/CA2947335A1/en
Priority to CA2947330A priority patent/CA2947330C/en
Publication of CA2622911A1 publication Critical patent/CA2622911A1/en
Application granted granted Critical
Publication of CA2622911C publication Critical patent/CA2622911C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
CA2622911A 2005-09-16 2006-09-18 Methods for reducing cd36 expression Active CA2622911C (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2947341A CA2947341C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947340A CA2947340C (en) 2005-09-16 2006-09-18 A method of treating conditions associated with ureteral obstruction
CA2947333A CA2947333A1 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947328A CA2947328C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947343A CA2947343C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947335A CA2947335A1 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947330A CA2947330C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71817005P 2005-09-16 2005-09-16
US60/718,170 2005-09-16
PCT/US2006/036291 WO2007035640A2 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression

Related Child Applications (7)

Application Number Title Priority Date Filing Date
CA2947333A Division CA2947333A1 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947343A Division CA2947343C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947341A Division CA2947341C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947328A Division CA2947328C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947335A Division CA2947335A1 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947330A Division CA2947330C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947340A Division CA2947340C (en) 2005-09-16 2006-09-18 A method of treating conditions associated with ureteral obstruction

Publications (2)

Publication Number Publication Date
CA2622911A1 CA2622911A1 (en) 2007-03-29
CA2622911C true CA2622911C (en) 2016-12-06

Family

ID=37889419

Family Applications (8)

Application Number Title Priority Date Filing Date
CA2622911A Active CA2622911C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947341A Active CA2947341C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947340A Active CA2947340C (en) 2005-09-16 2006-09-18 A method of treating conditions associated with ureteral obstruction
CA2947330A Active CA2947330C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947328A Active CA2947328C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947335A Abandoned CA2947335A1 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947333A Abandoned CA2947333A1 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947343A Active CA2947343C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression

Family Applications After (7)

Application Number Title Priority Date Filing Date
CA2947341A Active CA2947341C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947340A Active CA2947340C (en) 2005-09-16 2006-09-18 A method of treating conditions associated with ureteral obstruction
CA2947330A Active CA2947330C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947328A Active CA2947328C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947335A Abandoned CA2947335A1 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947333A Abandoned CA2947333A1 (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression
CA2947343A Active CA2947343C (en) 2005-09-16 2006-09-18 Methods for reducing cd36 expression

Country Status (10)

Country Link
US (10) US7541340B2 (https=)
EP (5) EP3095454A1 (https=)
JP (6) JP5416971B2 (https=)
KR (9) KR20150013353A (https=)
CN (6) CN104788540B (https=)
AU (1) AU2006292352B2 (https=)
CA (8) CA2622911C (https=)
DK (1) DK1931369T3 (https=)
HK (1) HK1206971A1 (https=)
WO (1) WO2007035640A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599216B9 (en) 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
PL2604286T3 (pl) * 2003-05-01 2015-03-31 Cornell Res Foundation Inc Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
CA3024434A1 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US7687243B1 (en) * 2005-06-06 2010-03-30 Crook Tonia M Automated method for detecting apoptosis in cells
CN104788540B (zh) * 2005-09-16 2019-10-18 科内尔研究基金会 用于减少cd36表达的方法
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
US20100331265A1 (en) * 2009-03-20 2010-12-30 Tompkins Ronald G Methods for the prevention and treatment of burn injuries and secondary complications
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
ES2964555T3 (es) 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
WO2011044044A1 (en) * 2009-10-05 2011-04-14 Cornell University Methods for the prevention or treatment of heart failure
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2011153209A2 (en) * 2010-06-01 2011-12-08 Cornell University Cd36 inhibition to control obesity and insulin sensitivity
EP2590664B1 (en) * 2010-07-09 2019-03-27 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
CN104244964A (zh) * 2012-02-22 2014-12-24 康肽德生物医药技术有限公司 用于预防或治疗眼科病状的方法和组合物
CN104271146A (zh) * 2012-03-30 2015-01-07 康肽德生物医药技术有限公司 用于预防和治疗神经病的方法和组合物
JP2015529655A (ja) 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
PL2936151T3 (pl) * 2012-12-18 2018-11-30 Biocrine Ab Sposoby leczenia i/lub ograniczania rozwoju cukrzycy
EP3586864A1 (en) * 2013-05-14 2020-01-01 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricle remodeling
WO2014210056A1 (en) * 2013-06-27 2014-12-31 Stealth Peptides International, Inc. Peptide therapeutics and methods for using same
EP3052115A4 (en) * 2013-09-30 2017-09-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
US9895410B2 (en) * 2013-12-12 2018-02-20 Cornell University Methods for preventing and treating oral cancers
US20170007663A1 (en) * 2013-12-16 2017-01-12 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
US11392555B2 (en) 2019-05-15 2022-07-19 Pure Storage, Inc. Cloud-based file services
WO2021021452A1 (en) * 2019-07-26 2021-02-04 The Board Of Trustees Of The Leland Stanford Junior University 1,8-cineol coated implants
WO2021101646A1 (en) 2019-11-20 2021-05-27 The Board Of Trustees Of The Leland Stanford Junior University Prophylactic skin treatment for radiation therapy
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
AU2024298726A1 (en) 2023-07-27 2026-02-19 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
FR2756284B1 (fr) 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
DE60042338D1 (de) 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
DE10051983A1 (de) 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
EP1994941A3 (de) * 2000-10-20 2012-07-25 Hamburger Stiftung zur Förderung von Wissenschaft und Kultur Arzneimittel, enthaltend mindestens ein oxidiertes Protein
AU2002256092C1 (en) 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
AU2002360460A1 (en) * 2001-12-03 2003-06-17 Nuvelo, Inc. Methods and materials relating to novel polypeptides and polynucleotides
JP4346870B2 (ja) * 2002-07-05 2009-10-21 キッコーマン株式会社 血糖値上昇抑制用組成物
WO2004017986A1 (en) * 2002-08-23 2004-03-04 Valorisation-Recherche, Societe En Commandite Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
EP1599216B9 (en) * 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
US20040229901A1 (en) 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
PL2604286T3 (pl) 2003-05-01 2015-03-31 Cornell Res Foundation Inc Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
US20050012597A1 (en) 2003-07-02 2005-01-20 Anderson Peter Traneus Wireless electromagnetic tracking system using a nonlinear passive transponder
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
EP1529533A1 (en) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
EP1712125A4 (en) 2003-12-12 2009-06-10 Japan Science & Tech Agency ANIMAL MODEL Animal expressing MEGSIN / RAGE / iNOS AND METHOD FOR EVALUATING COMPOUNDS WITH THE HELP OF ANIMALS
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US8157123B2 (en) * 2005-02-23 2012-04-17 The Glad Products Company Container
CN104788540B (zh) 2005-09-16 2019-10-18 科内尔研究基金会 用于减少cd36表达的方法
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
EP3741381B1 (en) 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
JP2012181082A (ja) * 2011-03-01 2012-09-20 Tokyo Electric Power Co Inc:The 仕切弁の分解点検補助装置およびその案内治具、並びに仕切弁の分解点検方法
CN202756379U (zh) 2012-07-13 2013-02-27 滨中元川金属制品（昆山）有限公司 一种自攻牙螺丝

Also Published As

Publication number Publication date
JP6157539B2 (ja) 2017-07-05
JP6385476B2 (ja) 2018-09-05
EP3260127A1 (en) 2017-12-27
CN104788540A (zh) 2015-07-22
US7811987B2 (en) 2010-10-12
KR101621493B1 (ko) 2016-05-16
CA2947333A1 (en) 2007-03-29
HK1123992A1 (en) 2009-07-03
CN102552874A (zh) 2012-07-11
KR20140106761A (ko) 2014-09-03
US20170305967A1 (en) 2017-10-26
US20230212220A1 (en) 2023-07-06
WO2007035640A2 (en) 2007-03-29
CA2622911A1 (en) 2007-03-29
KR101999756B1 (ko) 2019-07-12
CN102552874B (zh) 2015-04-22
US11447523B2 (en) 2022-09-20
JP2012233005A (ja) 2012-11-29
CA2947341A1 (en) 2007-03-29
US20250263433A1 (en) 2025-08-21
US20190248833A1 (en) 2019-08-15
US7541340B2 (en) 2009-06-02
CA2947328A1 (en) 2007-03-29
US20140256620A1 (en) 2014-09-11
HK1173367A1 (en) 2013-05-16
EP1931369A4 (en) 2012-05-02
CA2947335A1 (en) 2007-03-29
EP3095454A1 (en) 2016-11-23
KR20160057372A (ko) 2016-05-23
CA2947330C (en) 2018-06-05
AU2006292352B2 (en) 2012-02-09
AU2006292352A1 (en) 2007-03-29
CN101296704A (zh) 2008-10-29
JP2017066161A (ja) 2017-04-06
EP3725324A1 (en) 2020-10-21
EP1931369A2 (en) 2008-06-18
US9150614B2 (en) 2015-10-06
KR20160056863A (ko) 2016-05-20
KR20170105470A (ko) 2017-09-19
JP5805596B2 (ja) 2015-11-04
JP2013075915A (ja) 2013-04-25
DK1931369T3 (en) 2016-12-12
CN104788540B (zh) 2019-10-18
CN107412723A (zh) 2017-12-01
CA2947341C (en) 2019-03-05
JP2015205931A (ja) 2015-11-19
JP2015164953A (ja) 2015-09-17
CN101296704B (zh) 2012-09-05
US20210047369A1 (en) 2021-02-18
US20140249075A1 (en) 2014-09-04
JP2009509941A (ja) 2009-03-12
US20070129306A1 (en) 2007-06-07
HK1206971A1 (en) 2016-01-22
JP5416971B2 (ja) 2014-02-12
JP6175107B2 (ja) 2017-08-02
CA2947340C (en) 2019-05-07
US8603971B2 (en) 2013-12-10
EP3260127B1 (en) 2019-05-01
US20100317571A1 (en) 2010-12-16
CA2947328C (en) 2019-03-05
JP5809649B2 (ja) 2015-11-11
CA2947340A1 (en) 2007-03-29
CA2947343A1 (en) 2007-03-29
CA2947330A1 (en) 2007-03-29
KR20190084025A (ko) 2019-07-15
CN103784937A (zh) 2014-05-14
KR20150013353A (ko) 2015-02-04
CA2947343C (en) 2019-04-30
US20090264369A1 (en) 2009-10-22
KR20140042940A (ko) 2014-04-07
CN103784937B (zh) 2017-04-26
KR101426070B1 (ko) 2014-08-01
KR20080050497A (ko) 2008-06-05
WO2007035640A3 (en) 2007-11-22
CN104324360A (zh) 2015-02-04
EP1931369B1 (en) 2016-08-17
EP3549594A1 (en) 2019-10-09
HK1212718A1 (zh) 2016-06-17
KR20150013354A (ko) 2015-02-04

Similar Documents

Publication Publication Date Title
US11447523B2 (en) Methods for reducing CD36 expression
AU2012202035B2 (en) Methods for reducing CD36 expression
AU2019257440B2 (en) Methods for reducing CD36 expression
AU2016203803B2 (en) Methods for reducing cd36 expression
HK1242619A1 (en) Aromatic-cationic peptide for use in a method for reducing cd36 expression
HK1242610A1 (en) Methods for reducing cd36 expression
HK1173367B (en) Methods for reducing cd36 expression

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240913

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240913

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240913

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 19TH ANNIV.) - STANDARD

Year of fee payment: 19

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250916